Category: Pulmonary embolism

Rivaroxaban, a direct oral anticoagulant (DOAC) sold under the brand name Xarelto®, has demonstrated safety and effectiveness in clinical trials for treating and preventing recurrent pulmonary embolism (PE). Its use has streamlined treatment compared to older, more complex regimens.

According to treatment guidelines from the American Society of Hematology, both Eliquis (apixaban) and Xarelto (rivaroxaban) are considered first-choice treatments for pulmonary embolism (PE). The decision of "is ELIQUIS or Xarelto better for PE?" ultimately depends on an individual patient's specific health factors, risk profiles, and lifestyle preferences.